A new series of potential adenosine receptor antagonists with a [1,2,4]-triazolo-[3,4-f]-purine structure have been synthesized, and their affinities at the four adenosine receptor subtypes (A1, A2A, A2B and A3) have been evaluated. The design was based on the demonstrated approach to novel A3 adenosine receptor antagonists of adding a third ring to the xanthine structure. Unfortunately, all the synthesized compds. were completely inactive at all four adenosine receptor subtypes independently of their substitutions. Preliminary mol. modeling investigation has demonstrated that only a low degree of steric and electrostatic complementarity has been obsd. for all the new synthesized triazolo-purines with respect to other structurally related A3 receptor antagonists. This anal. yielded valuable information about structure-activity relationships and further design of potential adenosine receptor antagonists
Synthesis, biological studies and molecular modeling investigation of 1,3-dimethyl-2,4-dioxo-6-methyl-8-(substituted) 1,2,3,4-tetrahydro [1,2,4]-triazolo [3,4-f]-purines as potential adenosine receptor antagonists
CACCIARI, Barbara;
2005
Abstract
A new series of potential adenosine receptor antagonists with a [1,2,4]-triazolo-[3,4-f]-purine structure have been synthesized, and their affinities at the four adenosine receptor subtypes (A1, A2A, A2B and A3) have been evaluated. The design was based on the demonstrated approach to novel A3 adenosine receptor antagonists of adding a third ring to the xanthine structure. Unfortunately, all the synthesized compds. were completely inactive at all four adenosine receptor subtypes independently of their substitutions. Preliminary mol. modeling investigation has demonstrated that only a low degree of steric and electrostatic complementarity has been obsd. for all the new synthesized triazolo-purines with respect to other structurally related A3 receptor antagonists. This anal. yielded valuable information about structure-activity relationships and further design of potential adenosine receptor antagonistsI documenti in SFERA sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.